azacitidine has been researched along with Lymphoma, T Cell, Peripheral in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Brasacchio, D; DiCorleto, C; Gamgee, J; Gasiorowski, R; Gregory, GP; Gruber, E; Hawkes, EA; Hogg, SJ; Jia, W; Jong, I; Kailainathan, G; Kats, LM; Kumar, B; Levy, S; Lewis, A; Luong, Q; Maher, B; Opat, S; Polekhina, G; Reynolds, J; Sabouri-Thompson, Z; Shortt, J; Skinner, H; So, J; Uhe, M; Vervoort, S; Waltham, M; Wong, J | 1 |
| Goldfinger, M; Huber, BD; Jain, S; Kalac, M; Kanakry, J; Marchi, E; Montanari, F; O'Connor, OA; Tam, CS; Xiao, Z | 1 |
| Alonso, A; Cerchietti, L; Chen, Z; Elemento, O; Horwitz, S; Inghirami, G; Kotlov, N; Leonard, JP; Maksimov, V; Martin, P; Mehta-Shah, N; Melnick, A; Moskowitz, A; Mulvey, E; Nos, G; Revuelta, MV; Ruan, J; Rutherford, SC; Sboner, A; Sigouros, M; Sokol, L; Sorokina, M; van Besien, K; Xiang, J | 1 |
| Barta, SK | 1 |
| Bhagat, G; Deng, C; Falchi, L; Francescone, MM; Jacob, AT; Kim, HA; Kinahan, C; Klein, S; Lue, JK; Ma, H; Marchi, E; Menezes, D; Montanari, F; Nandakumar, R; O'Connor, OA; Park, DC; Rada, A; Scotto, L; Shustov, AR; Soderquist, CR; Sokol, L | 1 |
| Bruneau, J; Cheminant, M; Delarue, R; Derrieux, C; Gaulard, P; Hermine, O; Kosmider, O; Lefrere, F; Lemonnier, F; Radford, I | 1 |
| Choi, HY; Jeon, YK; Kim, CW; Kim, H; Kim, JE; Kim, YA; Kim, YN; Park, SO; Park, SS | 1 |
3 trial(s) available for azacitidine and Lymphoma, T Cell, Peripheral
| Article | Year |
|---|---|
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
Topics: Azacitidine; Decitabine; Genomics; Humans; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neutropenia; Treatment Outcome | 2022 |
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lymphoma, T-Cell, Peripheral; Prednisone; Tumor Microenvironment; Vincristine | 2023 |
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Depsipeptides; DNA Methylation; Female; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Mutation; Treatment Outcome | 2021 |
4 other study(ies) available for azacitidine and Lymphoma, T Cell, Peripheral
| Article | Year |
|---|---|
Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma.
Topics: Azacitidine; Depsipeptides; Humans; Lymphoma, T-Cell, Peripheral; Treatment Outcome | 2023 |
Is it prime time for T-cell lymphoma?
Topics: Azacitidine; CD8-Positive T-Lymphocytes; Humans; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral | 2023 |
Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma.
Topics: Aged; Antineoplastic Agents; Azacitidine; Dioxygenases; DNA Mutational Analysis; DNA-Binding Proteins; DNA, Neoplasm; Female; Humans; Immunoblastic Lymphadenopathy; Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell, Peripheral; Mutation; Proto-Oncogene Proteins | 2015 |
Resistance to Fas-mediated apoptosis is restored by cycloheximide through the downregulation of cellular FLIPL in NK/T-cell lymphoma.
Topics: Antibodies, Monoclonal; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Proliferation; Cell Survival; Cycloheximide; Death-Associated Protein Kinases; Decitabine; Down-Regulation; Enzyme Activation; Etoposide; fas Receptor; Humans; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Killer Cells, Natural; Lymphoma, T-Cell, Peripheral; Protein Synthesis Inhibitors | 2005 |